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Guidelines for screening for primary immunodeficiencies (PID) are well-defined and
several consensus diagnostic strategies have been proposed. These consensus
proposals have only partially been implemented due to lack of standardization in
laboratory procedures, particularly in flow cytometry. The main objectives of the EuroFlow
Consortium were to innovate and thoroughly standardize the flowcytometric techniques
and strategies for reliable and reproducible diagnosis and classification of PID of the
lymphoid system. The proposed EuroFlow antibody panels comprise one orientation
tube and seven classification tubes and corresponding databases of normal and PID
samples. The 8-color 12-antibody PID Orientation tube (PIDOT) aims at identification
and enumeration of the main lymphocyte and leukocyte subsets; this includes naïve
pre-germinal center (GC) and antigen-experienced post-GC memory B-cells and
plasmablasts. The seven additional 8(-12)-color tubes can be used according to the
EuroFlow PID algorithm in parallel or subsequently to the PIDOT for more detailed analysis
of B-cell and T-cell subsets to further classify PID of the lymphoid system. The Pre-GC,
Post-GC, and immunoglobulin heavy chain (IgH)-isotype B-cell tubes aim at identification
and enumeration of B-cell subsets for evaluation of B-cell maturation blocks and specific
defects in IgH-subclass production. The severe combined immunodeficiency (SCID) tube
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and T-cell memory/effector subset tube aim at identification and enumeration of T-cell
subsets for assessment of T-cell defects, such as SCID. In case of suspicion of antibody
deficiency, PIDOT is preferably directly combined with the IgH isotype tube(s) and in
case of SCID suspicion (e.g., in newborn screening programs) the PIDOT is preferably
directly combined with the SCID T-cell tube. The proposed ≥8-color antibody panels
and corresponding reference databases combined with the EuroFlow PID algorithm are
designed to provide fast, sensitive and cost-effective flowcytometric diagnosis of PID of
the lymphoid system, easily applicable in multicenter diagnostic settings world-wide.
Keywords: immunodeficiency, immunophenotyping, flow cytometry, diagnosis, classification, EuroFlow,
standardization
INTRODUCTION
Primary immunodeficiencies (PID) are inherited disorders of the
immune system, generally presenting with recurrent, sometimes
life-threatening infections. To date, more than 350 genes have
been identified that can be mutated in PID patients (1–3).
Depending on the genetic defect, one part of the immune system
or one cell type can be absent, decreased or dysfunctional. The
majority of PID patients (60–65%) have a defect in the lymphoid
system, involving B- and/or T-cells alone or in combination
with other cells (1–5). Flowcytometric immunophenotyping
plays a central role in the diagnostic workup of patients
suspected of PID, particularly those involving lymphoid cells
(1, 6). An accurate immunophenotypic diagnosis is essential for
guiding further functional testing as well as for genetic testing,
whether Sanger sequencing or next generation sequencing (NGS)
targeted to specific genes, whole exome sequencing (WES),
whole genome sequencing (WGS) or combinations thereof (2,
5, 7–10). Considering the clinical heterogeneity in genetically
homogeneous disease entities, immunophenotyping has an
additional role in understanding the clinical heterogeneity in
disease presentation and outcome (11–13). Immunophenotyping
can also support treatment decisions and monitoring, such as in
case of immunoglobulin (Ig) replacement therapy, hematopoietic
stem cell transplantation, and gene therapy (7, 8, 14–18).
In complex diseases with high numbers of affected genes
and still many genes to be discovered, some investigators
recommend the “Genetics First” approach via targeted NGS,
WES, and/or WGS, already at an early phase in the diagnostic
process (19, 20). Indeed, in absence of other in-depth diagnostic
methods, the “Genetics First” approach has clearly contributed
to better classification and more insight in some well-defined
disease categories with high genetic diagnosis yields, such as in
intellectual disability syndrome, hereditary spastic paraplegias,
and neuromuscular disorders (21–24). However, in the complex
field of PID most targeted NGS and/or WES studies have
genetic diagnosis yields varying from 15 to 30% (25–29),
sometimes increasing to 40% or higher, depending on the
number of targeted genes (varies from 170 to 571), young
age (higher yield in children), high frequency of X-linked
diseases, high frequency of families with PID history, and
highly consanguineous populations with high frequencies of
autosomal recessive diseases, such as in the Middle East
and North Africa region (9, 30–34). Importantly, virtually all
above-mentioned NGS and/or WES studies did not apply the
“Genetics First” approach, because the included PID patients
were defined according to the guidelines of the European Society
for Immunodeficiencies (ESID) and the International Union of
Immunological Societies (IUIS), which include flowcytometric
immunophenotyping (2, 5, 6). In fact, the genetic diagnosis
yield in immunophenotypically defined PID (sub)categories
ranges from >95% in severe combined immunodeficiency
(SCID), 85–90% in well-defined agammaglobulinemia patients,
∼75% in Hyper IgM syndrome, down to 10–20% among
the most frequently occurring PID, such as common variable
immunodeficiency (CVID) and immunoglobulin (Ig) isotype
deficiencies (5, 35–38).
Clearly, adequate clinical and immunophenotypic
characterization of PID patients should guide the diagnostic
process; this is supported by the diagnosis and classification
guidelines of ESID, IUIS, and Clinical Immunology Society (CIS)
(2, 6, 39). Compared to other organ systems, many different
genes are involved in the immune system, particularly in mature
B-cells during and after germinal center (GC) responses. Use of
WES and WGS will detect many allelic immune gene variants,
which might not be causally related to disease, implying that
significant efforts in immunobiological validation studies will be
needed. Furthermore, in-depth immunological and functional
studies are essential to define the consequences of genetic defects
for the immune system. At least part of these studies will be based
on flow cytometry. Especially in case of hypomorphic defects,
flow cytometry can help to better understand the effects of the
genetic defect on the composition of the lymphoid compartment
(11–13, 40, 41). Finally, flow cytometry is an important tool for
monitoring of targeted therapies, including cellular therapies
(15, 16, 18, 42).
Many PID centers have developed their own local multi-
color flowcytometric protocols and antibody panels for diagnosis
and classification of PID (8, 14, 43–45). These single-center
initiatives have led to a great variability in sample processing,
antibody panels, immunostaining procedures, instrument setup,
sample measurement and data analysis. In addition, the low
incidence and the clinical-immunological heterogeneity of PID
hamper prospective multicenter diagnostic validation in large
patient series and age-matched healthy controls (43–45). As
a consequence, the typical but rare immunophenotypic PID
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patterns are difficult to compare between centers at the national
and international level.
Whilst several recent international efforts have tried to
harmonize flowcytometric diagnostics of PID (43–48), they have
only been partially successful, mainly because these efforts have
been restricted to parts of the full pathway of pre-analytical,
analytical and post-analytical procedures, frequently focusing
on the antibody panels only. Most proposed antibody panels
aim at identification of severe defects in B and T lymphocytes,
NK-cells, and/or diagnostic screening for a specific inherited
disorder or a specific subgroup of disorders. Examples of such
disease-oriented antibody panels are meant for: (i) diagnostic
screening and classification of SCID based on quantification of
B-, T- and NK-cells with CD3, CD19, and CD56 or CD16; (ii)
diagnostic screening of congenital agammaglobulinemia, merely
based on enumeration of blood B lymphocytes; (iii) classification
of common variable immunodeficiency (CVID) according to
the proportion of transitional, non-switched/marginal zone-like
(smIgMD+) and class-switched (smIgMD−), and CD21dim B
lymphocytes; (iv) diagnostic screening of DiGeorge patients
based on relative blood counts of recent thymic emigrant
(RTE) CD4+ T-cells, and; (v) quantification of CD4/CD8-double
negative TCRαβ+ T-cells (DNT) for screening of autoimmune
lymphoproliferative syndrome (ALPS) (49, 50). Consequently,
such antibody panels do not provide a complete overview of the
many distinct subsets of circulating leukocytes, as required for
fast, efficient, and cost-effective PID diagnostics.
Several initiatives in other fields of clinical immunology
have also lead to consensus antibody panels for harmonized
flowcytometric immune monitoring, such as the CLIP study
(51), the NIH study (52), the ONE study (53), the Pasteur
initiative (54), and the NATURIMMUN consortium (55). These
antibody panels allow identification of several subpopulations
of B-, T-, and NK-cells (e.g., naïve vs. memory, activated
cells, TCRγδ vs. TCRαβ) together with the identification of
monocytes, dendritic cells, and granulocytes. However, the
proposed antibody combinations do not provide the fully
integrated information as needed for diagnosis and classification
of PID.
Here we describe newly designed, fully validated EuroFlow
procedures and tools for comprehensive immunophenotypic
diagnostic screening and classification of PID of the
lymphoid system. The proposed EuroFlow PID approach
relies on: 1. Optimized and validated ≥8-color antibody
panels; 2. Standardized procedures for sample preparation,
immunostaining, acquisition, and analysis of up to millions
of cells per sample; 3. Automated gating procedures for
reproducible identification of the many different immune
cell subsets in blood and bone marrow (BM). A diagnostic
algorithm and age-related reference values are provided for
guiding the flowcytometric PID diagnosis and classification
process; the entries in the EuroFlow diagnostic algorithm are
based on available clinical information and basic laboratory
data (Figure 1A), followed by stepwise application of the
newly designed antibody combinations with age-related
reference values of lymphocyte subsets in absolute counts
(Figures 1A,B).
This report describes the overall EuroFlow PID approach,
while detailed validation and reference value studies, including
healthy subjects and PID patient series, are provided per PID tube
(set) in separate EuroFlow PID reports (56–60).
METHODS
Design of the EuroFlow-PID Study
The design of the EuroFlow PID study took advantage of
the experience built in the field of leukemia and lymphoma
diagnosis, classification, and monitoring (61–65) and the
previously developed EuroFlow pre-analytical and analytical
standard operating procedures (SOPs) for sample collection,
transportation and staining of ≥106 nucleated cells (63,
64), together with EuroFlow 8-color instrument set-up and
calibration procedures (62), extended to ≥12-color flow
cytometry (56). Multicenter evaluation of the performance of
antibody panels was done in consecutive cycles of design-
testing-evaluation-redesign in large series of healthy controls
and patient samples in 10 EuroFlow centers, experienced in
PID diagnostics (56–59). For this purpose we used EuroFlow
multivariate analytical tools (66), incorporated in the Infinicyt
software and developed by Cytognos SL (Salamanca, Spain).
Stepwise application of newly-designed and validated
antibody combinations and available clinical and laboratory
information resulted in an algorithm for guiding
immunophenotypic diagnosis and classification of PID.
The final versions of the EuroFlow PID tubes were used to
build EuroFlow databases of normal and patient samples, for
automated classification of cell populations (i.e., automated
gating) and disease profiles (i.e., orientation of PID diagnosis
and classification), as described in detail elsewhere (64, 65, 67).
The multiple cycles of design-testing-evaluation-redesign
started in 2012 and took a total of 6 years and 20 in-person
EuroFlow PID meetings to reach the final results. No single
EuroFlow laboratory could have afforded the above described
efforts on its own. Solely thanks to intensive collaboration
and frequent exchange of results and information during the
EuroFlow meetings, the here described results could be achieved,
supported by local funds and by royalty income from pre-existing
EuroFlow patents in the leukemia-lymphoma field.
Flow Cytometers and Instrument Settings
and Calibration
Most laboratories (9 out of 10) used FACSCanto-II
flowcytometers (BD Biosciences, San Jose, CA), one laboratory
used a Navios flowcytometer (Beckman-Coulter, Hialeah,
FL). Standardized EuroFlow SOPs for instrument set-up and
calibration were used for both instruments, as provided in detail
via the EuroFlow website (www.EuroFlow.org) and by Kalina
et al. (62). With such protocols, fully comparable results are
obtained as previously demonstrated for both FACSCanto II,
Navios, and other ≥8-color instruments, even when run by
different operators (68).
For condensing sets of two 8-color tubes into single 12-
color tubes, BD LSR Fortessa X-20 or FACSLyric instruments
(BD Biosciences) were used in four centers where the EuroFlow
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FIGURE 1 | Continued
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FIGURE 1 | Strategy for flowcytometric immunophenotyping for screening and classification of lymphoid PID. (A) EuroFlow algorithm. On the basis of several entries
of clinical and laboratory parameters, blood samples of patients suspected to have PID are screened with the 8-color (or 10-color) PID Orientation tube (PIDOT).
Based on the obtained results, additional 8-color or 10-color T- and/or B-cell classification tubes are applied in a stepwise fashion, including the BM B-cell precursor
(BM-BCP) tube. In case of suspicion of PAD, both the PIDOT and the IgH-isotype tube(s) should be applied together. In case of suspicion of (S)CID and cases with
strongly reduced TRECs, both the PIDOT and the SCID/RTE tube can be applied together. See text for detailed description of the stepwise application of the
EuroFlow PID tubes. GC, germinal center; PAD, predominantly antibody deficiency; RTE, recent thymic emigrant; SCID, severe combined immunodeficiency. (B)
Age-related reference values. Absolute counts of all lymphocyte subsets are provided in the format of age-related percentile bars (median; 25–75 percentiles; 10–90
percentiles; 5–95 percentiles). The age groups are: cord blood (n = 15), newborns (n = 16), 1–11 months (n = 19), 12–23 months (n = 30), 2–4 years (n = 35), 5–9
years (n = 28), 10–17 years (n = 33), 18–60 years (n = 79), and >60 years (n = 66). In case of naïve TCRαβ+CD4+ T-cells, CM/TM TCRαβ+CD4+ T-cells, EM
TCRαβ+ CD4+ T-cells, TCRγδ+ T-cells, naïve TCRαβ+CD8+, CM/TM TCRαβ+CD8+ T-cells, EM TCRαβ+CD8+ T-cells, TCRαβ+CD4−CD8− T-cells, IgM+
plasmablasts, IgG+ plasmablasts, and IgA+ plasmablasts, the age groups of 10–17 years and >60 years contained only n = 18 and n = 21 individuals, respectively.
The original data set with the age-related reference values will be available via the EuroFlow website (www.EuroFlow.org) and will continuously be updated when more
data become available, also for other leukocyte subsets.
instrument set-up and calibration SOPs were extended for the
required extra colors, as described elsewhere (56, 58) and on the
EuroFlow website (www.EuroFlow.org).
EuroFlow Standard Operating Procedures
for Sample Preparation and Acquisition of
High Cell Numbers
To gain detailed insight into the composition of the lymphocyte
compartment, including robust identification of small cell
populations such as plasmablasts subsets, EuroFlow developed
SOPs for acquisition of high cell numbers (≥1–5 × 106 total
nucleated cells) and/or large sample volumes (up to 2mL per
tube) (56, 63, 64). These procedures can be used for fresh (<36 h,
preferably <24 h) blood and BM samples (69).
For acquisition of high cell numbers, the EuroFlow bulk-
lysis-and-stain technique is recommended (56, 64), as described
also on the EuroFlow website (www.EuroFlow.org). Briefly, the
sample (up to 2mL) is diluted in a total volume of 50mL of
an ammonium chloride hypotonic solution (1:25mL vol:vol per
50mL tube), gently mixed and incubated for 15min in a roller.
Then, nucleated cells were centrifuged and washed twice in
phosphate buffered saline (PBS) containing 0.5% bovine serum
albumin (BSA). Subsequently, the surface membrane markers
on nucleated cells are stained with the corresponding antibody
mixtures. Overall,≥1–5× 106 nucleated cells were measured for
each antibody combination.
Construction of Antibody Panels
Antibody panels were designed for unequivocal identification
and full dissection of lymphocyte subsets and their
maturation-associated pathways, in parallel to other leukocyte
subpopulations, which might show uniquely altered patterns in
different PID categories. Specific combinations of fluorochrome-
conjugated reagents were selected based on the need for
brightness, stability, limited fluorescence spill-over and
compensation requirements, as described elsewhere (58, 62, 70).
These antibody combinations were evaluated in parallel in
multiple centers (at least 4 centers per testing round) and they
were optimized via multiple consecutive cycles of design-testing-
evaluation-redesign. In each testing cycle, the Infinicyt software
was used to identify antibodies for optimal recognition and clear-
cut separation of the target cell subsets, while other antibodies
were discarded because of insufficient separation of target cell
subsets, poor contribution and/or redundancy, as exemplified for
the PIDOT in Van der Burg et al. (59). Once optimal recognition
and separation of the different target cell subsets was achieved
with high reproducibility among the different laboratories, the
antibody combination was frozen for final validation in large
series of normal and PID patient samples (56, 59, 60). This
included an intra-laboratory and inter-laboratory coefficient of
variation (CV) for the identification of different minor and major
lymphoid subsets of <10 and <30%, respectively, as described
for example for the PIDOT (60) and the IgH-isotype tube (57).
Optimal recognition and clear-cut separation of target
cell populations avoids arbitrary marker settings between cell
populations with vague cutoff values, which easily vary between
different laboratories, particularly when different antibody clones
and fluorochrome conjugates are used. Therefore, the above
described procedures are essential for obtaining reproducible
results, which allow comparison of flowcytometric patterns of
PID patients between centers at the international level.
Patients and Age-Matched
Healthy Controls
The proposed antibody panels were extensively evaluated in
multicenter studies by analyzing blood (n = 541) and BM (n
= 43) samples. Blood samples from healthy controls (n = 300)
included different age groups: cord blood (n = 15), newborns (n
= 16), 1–11 months (n = 19), 12–23 months (n = 30), 2–4 years
(n = 35), 5–9 years (n = 28), 10–17 years (n = 33), 18–60 years
(n= 79), and >60 years (n= 66).
The PID patients included in the study were all genetically-
defined cases, except for the most frequent subgroups of
predominantly antibody deficiencies (CVID, Ig-subclass
deficiencies), for which the ESID and IUIS diagnostic and
classification criteria (1, 5) were applied. The PID patients (n
= 241) concerned: SCID (n = 24), CVID (n = 66), DiGeorge
syndrome (n = 6), ALPS (n = 5), Wiskott-Aldrich Syndrome
(n = 3), selective IgA-deficiency (n = 68), BTK-deficiency (n
= 10), CD40L-deficiency (n = 6), other less profound CID
(n = 6), other CID with syndromic features (n = 11), and
several other PID subgroups (n = 36), such as IgG subclass
deficiency with IgA deficiency (n = 10), PI3K delta syndrome
(n = 5), GATA2 deficiency (n = 5), other diseases of immune
dysregulation (n = 4), together with other PID patients not
classified as primary defects of the lymphoid system, e.g., chronic
granulomatous disease (n = 5), defects of innate immunity (n =
3) and complement deficiencies (n= 4) (59).
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FIGURE 2 | Generation of a reference principal component analysis 1 (PCA1) vs. PCA2 representation in an n-dimensional space for discrimination of the lymphocytes
subsets identified with PIDOT. (A) Data files from 5 healthy donors were merged and lymphocyte subsets of interest identified using bivariate plots. (B) The merged
data were used to define an n-dimensional space with the best principal component analysis 1 (PC1) vs. PC2 representation to discriminate these subsets. The PCA
representation of the data is resumed in 2 × Standard Deviation (SD) curves to be used as a reference for supervised automatic analysis of the samples.
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Normal blood samples were obtained from healthy adult
volunteers or from children upon informed consent of the
parents. The BM samples concerned remaining cell material
of sibling BM stem cell transplantation donors who consented
to participate in the study. All normal and patient samples
were collected in tubes containing EDTA as anti-coagulant and
processed within 24 h after sampling (69).
Ethical approval and informed consent procedures were
according to the local ethical guidelines of the participating
EuroFlow institutions and the Declaration of Helsinki
(University of Salamanca, Salamanca, Spain; Charles University,
Prague, Czech Republic; La PazHospital, Madrid, Spain; Erasmus
MC, Rotterdam, The Netherlands; University Hospital Ghent,
Belgium; and St. Anne’s University, Brno, Czech Republic).
The study was approved by the local ethics committees of the
participating centers: University of Salamanca, Salamanca,
Spain (USAL CSIC 20-02-2013); Charles University, Prague,
Czech Republic (15-28541A); Erasmus MC, Rotterdam, The
Netherlands (MEC-2013-026); University Hospital Ghent,
Belgium (B670201523515); and St. Anne’s University, Brno,
Czech Republic (METC 1G2015).
Data Acquisition and Data Analysis With
EuroFlow Software Tools
Data acquisition was performed at low-medium speed (5,000–
10,000 cells/s) using either FACSDiva (version 8) or the Navios
software. For data analysis, the Infinicyt software (version
2.0) was used. Briefly, standardized Boolean gating strategies
were defined and used for manual gating of the distinct cell
populations identified in each tube. The merge function of the
Infinicyt software was used to merge data files into reference
databases. For each cell population its relative distribution among
all nucleated cells, lymphocytes, and the corresponding B-, T-,
and NK-cell subsets, were calculated and the MFI values per
marker reported for each cell subset identified. In addition,
absolute lymphocyte counts were calculated using a CD45PerCP,
CD3FITC, CD19APC, and CD16+CD56PE TruCOUNT tube
(BD Biosciences) following the instructions of the manufacturer.
For automated identification of the cell populations present
in the PID tubes, PID databases were built, containing normal
blood samples stained with the same antibody combination(s).
Reference ranges with abnormality alarms were set per age-
group, based on the analysis of a large cohort of 250 healthy
control samples: cord blood (n = 15), childhood <18 years (n
= 146), and adults ≥18 years (n= 89).
Multicenter Validation of PID Tubes
In order to ensure full comparability between theMFI per marker
per cell subset in different samples stained at distinct centers,
all EuroFlow centers were trained in the EuroFlow instrument
set-up and calibration as well as sample preparation SOPs.
Afterward, each center was enrolled in the EuroFlow Quality
Assurance program (71, 72). EuroFlow QA program showed that
overall QA results of EuroFlow laboratories showed CVs below
30% in more than 90 and 70% of cell populations in 59/72 (82%)
and in 71/72 (99%) QA sets, irrespectively of the flowcytometer
used and the participant.
In addition, normal blood samples stained with the PID
Orientation tube upon strictly following the EuroFlow SOPs,
TABLE 1 | Composition of the 8-color PID Orientation tube and technical information on reagents.
BV421 BV510 FITC PE PerCPCy5.5 PECy7 APC APCH7
CD27 CD45RA CD8 and CD16 and CD4 and CD19 and CD3 CD45
SmIgD CD56 SmIgM TCRγδ
Marker Fluorochrome Clone Source Catalog number Application in EuroFlow panel µl/test
CD3 APC SK7 BD Biosciences 345767 Orientation, SCID/RTE, T cell subset tubes 2.5
CD4 PerCPCy5.5 SK3 BD Biosciences 332772 Orientation tube 7
CD8 FITC SK1 BD Biosciences 345772 Orientation tube 5
CD16 PE 3G8 BD Biosciences 555407 Orientation tube 5
CD19 PECy7 J3-119 Beckman Coulter IM3628 Orientation, BM-BCP, Pre-GC, Post-GC, IgH-isotype tubes 5
CD27 BV421 M-T271 BD Biosciences 562513 Orientation, Pre-GC, Post-GC, T cell subset tubes 1
CD27* BV421 O323 BioLegend 302824 Orientation, Pre-GC, Post-GC, T cell subset tubes 1
CD45 APCH7 2D1 BD Biosciences 641417 Orientation tube 2
CD45RA BV510 HI100 BD Biosciences 563031 Orientation tube 2.5
CD45RA* BV510 HI100 BioLegend 304142 Orientation tube 2.5
CD56 PE C5.9 Cytognos CYT-56PE Orientation tube 5
CD56* PE Leu11c BD Biosciences 332779 Orientation tube 5
SmIgD FITC IA6-2 BioLegend 348205 Orientation tube 1.25
SmIgM PerCPCy5.5 MHM-88 BioLegend 314511 Orientation tube 2
TCRγδ PECy7 11F2 BD Biosciences 655410 Orientation, SCID/RTE, T cell subset tubes 1
*Alternative reagents tested to provide same results.
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FIGURE 3 | PCA representation of PIDOT results, showing the distinct blood leukocyte subsets in the reference data file and supervised analysis of blood samples
from a healthy donor and three different PID patients. (A) Reference principal component analysis. PCA1 vs. PCA2 representation was generated from five healthy
donors data files, analyzed with the EuroFlow PIDOT. (B) Different patient samples were analyzed against the healthy donor PCA reference. Blood samples from a
healthy donor, a patient with mutated STAT3, a SCID patient with IL2 receptor gamma chain (IL2RG) deficiency, and a SCID patient with recombination activating gene
2 (RAG2) deficiency were stained and acquired under identical/comparable conditions. The STAT3 deficient patient shows the typical pattern of reduced naïve T-cells,
virtually no IgH-class switched B-cells, and no eosinophils. The IL2RG deficient SCID patient has virtually no T-cells, particularly no naïve T-cells (<1 cell/µL; see
Figure 1B), B-cells are present, but no memory B-cells or plasmablasts, and NK-cells are virtually absent. The RAG2 deficient SCID patient has no B-cells and no
T-cells, while NK-cells are present in normal numbers. DNT, double negative T-cells, negative for CD4 and CD8, but positive for CD3.
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showed≤1% abnormality alarms for the normal lymphocyte and
myeloid cell populations.
RESULTS
EuroFlow Algorithm for PID Diagnosis
and Classification
Suspicious patient features, such as recurrent and unusual
infections, particularly with the same pathogen, auto-immunity,
inflammation, lymphoproliferation, and/or organomegaly are
triggers for application of the “PID Orientation tube” (PIDOT).
In line with the EuroFlow PID algorithm (Figure 1A), the results
of the PIDOT will guide the next steps:
- When the PIDOT identifies strongly reduced B-cell counts (<1
cell/µL; see Figure 1B) in the absence of a T-cell problem,
the diagnosis of agammaglobulinemia is likely. In such case
analysis of the B-cell precursor (BCP) compartment in BM
with the PID-BCP tube might be informative to define the
position and degree of blockade in early B-cell development,
which differs between different genetic defects (37, 38).
FIGURE 4 | Application of the Pre-GC tube, showing the major B-cell subsets in blood of healthy controls, and PID patients using classical 2-dimensional plots vs.
n-dimensional PCA. Analysis of circulating B-cell subsets (FS/SSloCD19+) identified within 2 × 106 blood leukocytes using the markers from the Pre-GC tube:
Immature (CD5+ CD27− CD38++ smIgM++ smIgD+), CD5+ and CD5− naïve B-cells (CD27− CD38+d smIgM+ smIgD++), Ig non-switched and Ig-switched
memory B-cells (CD5− CD27+ CD38− smIgM+ smIgD++ and CD5− CD27+/− CD38− smIgM− smIgD−, respectively), and plasmablasts (CD5− CD27++
CD38+++). (A) The identification of biologically relevant subsets of B-cells using the minimum number of bivariate plots required for a 5 marker-combination (three
bivariate plots/cell population). (B) The same data via PC1 vs. PC2 representation of a 5-dimensional space in blood of six healthy controls (left panel), in blood of a
patient with common variable immunodeficiency (CVID; middle) and in blood of a patient with agammaglobulinemia (right), all stained with the Pre-GC tube under
comparable conditions. The CVID patient lacks plasmablasts in blood (<0.01 cell/µL blood) and has reduced IgH-class switched MBC. The agammaglobulinemia
patient has no plasmablasts, no MBC, and also the naïve B-cell compartment is strongly reduced.
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- In case the PIDOT reveals reduced B-cell (subset) counts (<5th
percentile ≈ <2 SD values; see Figure 1B), application of the
“Pre- and Post-GC B-cell tubes” is advised.
- The results of the “Pre- and Post-GC B-cell tubes” might
directly support the diagnosis of Hyper IgM syndrome or
CD19 complex deficiency (Figure 1A).
- If the “Pre- and Post-GC B-cell tubes” do not detect
plasmablasts in blood (<0.01 cell/µL; see Figure 1B), in
the presence of reduced memory B-cell subsets, the CVID
diagnosis should be considered (57). The IgH isotype tube can
further support such diagnosis (57).
- If the “Pre- and Post-GC B-cell tubes” reveal IgH class
aberrancies in memory B-cell subsets or plasmablast subsets
(<5th percentile ≈ <2 SD values; see Figure 1B), application
of the IgH isotype tubes is advised.
- When the PIDOT tube identifies virtually no (naïve) T-cells
(<1 cell/µL; see Figure 1B), application of the “SCID/recent
thymic emigrant (RTE)” tube is advised to confirm the lack of
T-cell production. It should be noted that SCID patients might
have normal or reduced T-cell counts in the virtual absence
of naïve T-cells (<1 cell/µL; see Figure 1B) with T-cell “right
shifts” to more mature T-cell subsets; this is typically seen in
subgroups of SCID patients such as “leaky SCID” and Omen
syndrome (59) and generally appear to concern oligoclonal
expansions of mature T-cells (73, 74).
- In case of reduced T-cell (subset) counts (<5th percentile≈<2
SD values; see Figure 1B), application of the T-cell subset tube
is proposed.
The combined results of all (n = 241) evaluated PID patients
demonstrated that in patients with suspicion of predominantly
antibody deficiency, e.g., recurrent respiratory infections, low
serum Ig levels, and poor antibody response to vaccination, the
PID Orientation tube should (at diagnostic screening) directly be
combined with the “IgH-isotype B-cell tubes”.
Similarly, in case of infants with failure to thrive and severe
recurrent infections with unusual pathogens, the “SCID/RTE tube”
should directly be combined with the PID Orientation tube at
diagnostic screening. Such combined SCID/RTE + PIDOT tube
approach will also be useful for positive cases from newborn
screening (NBS) programs, i.e., cases with strongly reduced T-cell
receptor excision circles (TRECs) in blood (14, 75–77).Whenever
specific diseases such as ALPS or XLP are suspected (e.g., increased
CD4−/CD8− counts or increased total T-cells counts; Figure 1B)
additional studies need to be performed (not addressed in
this manuscript).
PID Orientation Tube
The PID Orientation tube has been designed for full dissection
of all major blood leukocyte (sub)populations (n= 27) in a single
tube (Figure 2). The choice of markers, corresponding antibodies
and fluorochromes aim at reliable detection and quantitation of
these blood leukocyte subsets and their potential alterations.
After four cycles of design-testing-evaluation-redesign, the
final version of the 8-color PID Orientation tube consisted of 12
markers: CD27, CD45RA, CD8, IgD, CD16, CD56, CD4, IgM,
CD19, CD3, CD45, and either TCRαβ or preferably TCRγδ,
wherein the following antibody pairs CD8/IgD, CD16/CD56,
CD4/IgM, and CD19/TCRγδ or CD19/TCRαβ are conjugated to
the same fluorochrome (Table 1). These reagents aim at detailed
dissection of eight major blood leukocyte subsets (Figure 2):
B-cells, T-cells, NK-cells, monocytes (including non-classical
CD16+ monocytes), dendritic cells, basophils, neutrophils and
eosinophils. Additionally, B-cells and T-cells can be classified
into a total of four and twelve different maturation pathway-
associated subsets, respectively. Accordingly, B-cells are divided
into pre-GC B-cells (including both immature/transitional and
naïve B-cells), unswitched (including IgM+IgD+, IgM-only and
IgD-only) and Ig-switched memory B-cells (MBC) and generally
also plasmablasts (Figure 2). The T-cell compartment can be
divided into different functional subsets according to the TCRγδ
or TCRαβ lineage and according to CD4 and CD8 expression.
These T-cell subsets can be further subdivided according to their
maturation stage into naïve, central/transitional memory, and
effector memory/terminally differentiated T-cells (Figure 2).
Therefore, the PID Orientation tube detects defects in the
production of B-cells, T-cells and NK-cells, together with
alterations (defective but also increase) in the production
of monocytes, dendritic cells, neutrophils, eosinophils, and
basophils. Three typical PID patient examples (STAT3, IL2RG,
and RAG2 deficiency) are shown in Figure 3 to illustrate
the disease-associated immunophenotypic profiles. However, in
most cases the PID Orientation tube does not allow precise
(sub)classification of the T-cell and B-cell defects, implying that
further characterization is required with additional B-cell and T-
cell tubes, according to the EuroFlow PID algorithm (Figure 1A),
as described below [see also (59)].
Some diagnostic laboratories in the PID field use a
simple B-T-NK tube as first screening step, while most
laboratories use several 4- to 6-color tubes in parallel to
perform initial screening (generally using 12–18 antibodies
with multiple repeats). The here proposed 8-color tube
with 12 antibodies provides information on up to 20
different leukocyte (sub)populations, clearly separated in
multidimensional principal component analysis (Figures 2, 3),
thereby providing the basis for further classification of PID of the
lymphoid system.
B-Cell Tubes
For antibody deficiencies and combined T/B-cell defects,
detailed analysis of the B-cell compartment in blood and
BM is required. B-cells originate from the BCP differentiation
pathway in BM into immature and naïve B-cells that enter
the periphery, including blood. In the periphery, the B-cells
encounter antigen which induces a GC reaction. Consequently,
blood contains naïve B-cells that did not yet undergo a
GC reaction (pre-GC B-cells) or that have already been
exposed to antigen, such as antigen-experienced memory B-
cells (MBC), plasmablasts and plasma cells. The antigen-
experienced subsets can be further subdivided according to class
switching of their IgH-isotypes (and subclasses): IgM, IgD, IgE,
IgG (including IgG1, IgG2, IgG3, IgG4), and IgA (including
IgA1, IgA2).
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TABLE 2 | Composition of the 8-color B-cell tubes and technical information on reagents.
BV421 BV510 FITC PE PerCPCy5.5 PECy7 APC APCAF750
Pre-GC CD27 SmIgM CD38 CD5 SmIgD CD19 CD21 CD24
Post-GC CD27 SmIgM SmIgE and SmIgA SmIgG and SmIgA SmIgD CD19 CD21 CD38
IgH-isotype-I CD27 SmIgM SmIgG4 and SmIgG2 SmIgG1 and SmIgG2 SmIgD CD19 CD21 CD38
IgH-isotype-II CD27 SmIgM SmIgG3 and SmIgA1 SmIgA2 and SmIgA1 SmIgD CD19 CD21 CD38
Marker Fluorochrome Clone Source Catalog number Application in EuroFlow-PID panel µl/test
CD5 PE UCHT-2 BioLegend 300608 Pre-GC tube 5
CD19 PECy7 J3-119 Beckman Coulter IM3628 Orientation, BM-BCP, Pre-GC, Post-GC, IgH-isotype
tubes
5
CD21 APC B-ly4 BD Biosciences 559867 Pre-GC, Post-GC, IgH-isotype tubes 10
CD24 APCAF750 ALB9 Beckman Coulter B10738 Pre-GC, 5
CD27 BV421 M-T271 BD Biosciences 562513 Orientation, Pre-GC, Post-GC, IgH-isotype, T-cell
subset tubes
1 (Pre/Post-GC)/2
(IgH-isotype)
CD38 FITC HB7 BD Biosciences 340909 Pre-GC tube 5
CD38 APCH7 HB7 BD Biosciences 656646 Post-GC tube, IgH-isotype 3
SmIgA FITC IS11-8E10 Miltenyi 130-093-071 Post-GC tube 1
SmIgA PE IS11-8E10 Miltenyi 130-093-128 Post-GC tube 1
SmIgA1 FITC SAA1 Cytognos CYT-IGA1F IgH-isotype tube 3
SmIgA1 PE SAA1 Cytognos CYT-IGA1PE IgH-isotype tube 3
SmIgA2 PE SAA2 Cytognos CYT-IGA2PE IgH-isotype tube 3
SmIgD PerCPCy5.5 IA6-2 BioLegend 348208 Pre-GC, Post-GC, IgH-isotype tubes 1.5
SmIgE FITC polyclonal Life Technologies H15701 Post-GC tube 2
SmIgG PE G18-145 BD Biosciences 555787 Post-GC tube 20
SmIgG1 PE SAG1 Cytognos CYT-IGG1PE IgH-isotype tube 3
SmIgG2 FITC SAG2 Cytognos CYT-IGG2F IgH-isotype tube 3
SmIgG2 PE SAG2 Cytognos CYT-IGG2F IgH-isotype tube 3
SmIgG3 FITC SAG3 Cytognos CYT-IGG3F IgH-Isotype tube 3
SmIgG4 FITC SAG4 Cytognos CYT-IGG4F IgH-isotype tube 3
SmIgM BV510 MHM-88 BioLegend 314521 Pre-G, Post-GC, IgH-isotype tubes 1.3 (Pre/Post-GC)/2
(IgH-isotype)
Therefore two 8-color panels were designed for the
identification of (i) different pre-GC B-cell subsets, including
immature/transitional, naïve CD5+ and naïve CD5− B-
cells, and (ii) antigen-experienced subsets, including MBC
and plasmablasts (Figure 4). The latter panel includes sub-
classification of both MBC and PC according to IgH-isotype
(IgM, IgD, IgG, IgA, IgE). Further IgH subsetting according to
the specific subclasses (IgM, IgD, IgG1, IgG2, IgG3, IgG4, IgA1,
and IgA2) was designed in a combination of two separate 8-color
tubes or a single 10 or 12-color tube (56).
Accordingly, the EuroFlow 8-color PID B-cell tube set
consists of five tubes for detailed subsetting of blood pre-
GC B-cells (Pre-GC B-cell tube), antigen-experienced
B-cells (Post-GC B-cell tube), including detailed IgH-
isotype and subclass analysis of MBC and plasmablasts
(IgH-isotype B-cell tubes 1 and 2), and BM BCP analysis
(BCP tube) (Figure 1A).
Briefly, the “Pre-GC B-cell tube” contains CD27, IgM, CD38,
CD5, IgD, CD19, CD21, and CD24 markers (Table 2), which
allows detection of immature/transitional B-cells, CD5+ and
CD5− naïve B-cells (including their CD21 and CD24 subsets),
unswitched (including IgM+IgD+, IgM-only, and IgD-only) and
switched MBC and PC. The “Post-GC B-cell tube” contains
CD27, IgM, IgA, IgG, IgD, CD19, CD21, CD38, and optionally
IgE, wherein two distinctly labeled antibodies against IgA allow
to have the IgE/IgA pair and IgG/IgA pair conjugated to the same
fluorochrome (Table 2) (78). The “IgH-Isotype B-cell tube-1
and tube-2” (Figure 5A) both contain CD27, IgM, IgD, CD19,
CD21, and CD38 together with IgG4, IgG2, IgG1, or with
IgA2, IgA1, IgG3, respectively. In this composition two distinctly
labeled antibodies against IgG2 and IgA1 are used, wherein
the antibodies within the pairs IgG1/IgG2 and IgG2/IgG4
or IgA1/IgG3 and IgA1/IgA2 are conjugated to the same
fluorochrome (Table 2).
Finally, the BCP-BM tube consists of the seven cell surface
membrane markers CD20, IgM, CD38, IgD, CD19, CD34, and
CD10 and the three intracellular markers cyIgµ, nuTdT, and
cyCD79a (Table 3). This combination of markers allows detailed
analysis of the BM-BCP compartment from the CD19-negative
stage until the naïve B-cells and can visualize complete and partial
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FIGURE 5 | Application of the IgH-isotype tube for the dissection of switched memory B-cells and plasmablasts in blood from healthy donors and PID patients. (A)
Bivariate plots showing the distribution of switched memory B-cells (smIgMD−CD19+CD38−) and plasmablasts (CD19+CD27++CD38+++) according to the
surface membrane expression of the different IgH-isotypes (IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) in 5 × 106 peripheral blood leukocytes analyzed with the
IgH-isotype tubes in samples from a healthy adult. (B) Three dimensional PCA representation of IgH-isotype subsets in memory B-cells (top) and plasmablasts (lower)
in a healthy adult donor (left), a selective IgA-deficient patient (middle), and a CVID patient (right). No plasmablasts were detected in blood from the CVID patient (count
of <0.01 cells/µL blood), while variable defects were detected in the memory B-cell compartment, particularly involving switched memory B-cells. The defects in the
IgA-deficient patient mainly concerned the IgA-class-switched plasmablasts.
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TABLE 3 | Composition of the 10-color BM-BCP tube and technical information on reagents.
PacB BV510 BV605 FITC PE PECF594 PerCPCy5.5 PECY7 APC APCC750
CD20 SmIgM CD38 nuTdT CyCD79a SmIgD CyIgM CD19 CD34 CD10
Marker Fluorochrome Clone Source Catalog number Application in EuroFlow-PID panel µl/test
CD10 APCC750 HI10a Cytognos CYT-10AC750 BM-BCP 3
CD19 PECy7 J3-119 Beckman Coulter IM3628 Orientation, BM-BCP, Pre-GC, Post-GC, IgH-isotype tubes 5
CD20 PacB 2H7 Biolegend 302320 BM-BCP tube 1
CD34 APC 8G12 BD Biosciences 345804 BM-BCP tube 5
CD38 BV605 HIT2 Biolegend 303532 BM-BCP tube
CyCD79a PE HM57 Dako R7159 BM-BCP tube 3
SmIgD PECF594 IA6-2 BD Biosciences 562540 BM-BCP tube 5
SmIgM BV510 MHM-88 BioLegend 314521 BM-BCP, Pre-GC, Post-GC, IgH-isotype tubes 2
CyIgM PerCPCy5.5 MHM-88 BioLegend 314512 BM-BCP tube 2
nuTdT FITC HT-6 Dako F7139 BM-BCP tube 10
blocks in BCP differentiation as well as aberrant expression
profiles (Wentink et al., unpublished results).
For reasons of efficiency, the two IgH-isotype tubes can be
combined into a single 10-color IgH-isotype tube with CD27,
IgM, IgG3, IgG2, IgG1, IgD, CD19, CD21, CD38, IgA1, IgA2, and
IgG4, with two distinctly labeled antibodies against IgG2 and two
distinctly labeled antibodies against IgA1 (“10-color IgH-isotype
tube”). Preferably, the four blood B-cell tubes (Pre-GC, Post-GC,
and the two IgH-isotype tubes) can be combined into a single 12-
color tube by the further addition of CD5 and CD24 (“12-color
IgH-isotype B-cell tube”) (56, 57).
In summary, the Pre-GC and Post-GC tubes can visualize
blockades in differentiation of transitional to mature naïve B-
cells in e.g., a subset of XLA patients, and variable defects
in IgH-switched MBC and plasmablasts, such as in patients
with Hyper IgM syndrome, CD19 complex deficiencies, IgH
class aberrancies, and CVID with almost systematic absence of
plasmablasts (<0.01 cell/uL) (Figures 1B, 4B) (57). In addition,
the IgH-isotype tubes can uncover more subtle defects in
IgH-class switching e.g., in selective IgA- and IgG-subclass
deficiencies (Figure 5B) (57). Finally, the BCP tube detects early
blockades in BCP maturation in BM.
T-Cell Tubes
In many cases with suspicion of PID of the lymphoid system,
analysis of T-cell subsets is an essential part of making a
correct diagnosis. If the PID Orientation tube indicates reduced
T-cell (subset) counts or abnormal T-cell maturation, further
investigation of the blood T-cell compartment is recommended.
The SCID/RTE tube is meant for cases with strongly reduced
(naïve) T-cell production (<1 cell/µL; see Figure 1B), whereas
the T-cell subset tube should be applied when the PID orientation
tubes reveals an imbalanced composition of the memory and
effector T-cell compartments.
In case of high suspicion of SCID in children of <1 year
with severe recurrent infections by unusual pathogens and
failure to thrive, the SCID/RTE tube should be directly applied
in combination with the PID Orientation tube (Figures 1A,
6). In such patients the detected blood T-cells might be
(non-autologous) transplacentally-derived maternal T-cells. The
predominant presence of (activated) memory T-cells (either
autologous or maternal) in the absence of T-cells recently
emigrated from the thymus (RTE), further supports the SCID
diagnosis (Figure 6).
Upfront identification of the major TCRγδ, TCRαβ, CD4,
and CD8 T-cell lineages is required for further detailed
dissection of their maturation pathways into (CD31+) RTE,
naïve, memory and effector subsets, including activated (HLA-
DR+) T-cells (Figure 6). The T-cell subset tube further
dissects the blood T-cell lineages into central memory
(CM), transitional memory (TM), effector memory (EM),
terminal differentiated (TD), and terminal effector (TE)
subsets (Figure 7).
Briefly, two 8-color T-cell tubes have been designed: (i)
the SCID/RTE tube with the five backbone markers CD3,
CD4, CD8, CD45RO, and TCRαβ or TCRγδ, supplemented
with the subsetting markers CD31, CD62L, HLA-DR for
identification of RTEs and activated T-cells (Table 4); and
(ii) the T-cell subset tube with the same five backbone
markers, combined with CD27, CD28, and CCR7 (Table 4) for
detailed dissection of the above mentioned memory and effector
compartments (Figures 6, 7).
In summary, while the first tube identifies major defects in
T-cell production, the second tube focusses on milder defects in
T-cell production and/or altered T-cell responses (Figures 6, 7).
EuroFlow Reference Databases as
Essential Tool for Easy, Fast, and
Reproducible Analysis of Patient Samples
Similarly to the EuroFlow leukemia-lymphoma diagnosis and
monitoring databases (64–66), reference databases have been
generated for the EuroFlow PID tubes to facilitate: 1. Automated
gating of all leukocyte subsets; 2. Identification of PID-associated
immune cell profiles vs. normal age-matched reference values
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FIGURE 6 | Application of the RTE-SCID tube in healthy controls and T-cell defects. Analysis of circulating T-cell subsets (FS/SSloCD3+) identified within 1x106 blood
leukocytes using the markers from the RTE-SCID tube: Recent Thymic Emigrants (RTE) CD4+ T-cells (CD4+ CD8− CD45RO− CD62L+ CD31+ HLA-DR−), and
naïve (CD45RO− CD62L+ CD31+ HLA-DR−), Central/Transitional Memory (CM/TM) (CD45RO+ CD62L+), Effector Memory (EM) (CD45RO+ CD62L−), and
Terminally Differentiated (TD) (CD45RO− CD62L−) CD4+ and CD8+ T-cells. (A) The identification of biologically relevant T-cell subsets in six healthy controls using the
minimum number of bivariate plots required for a 6 marker-combination (three bivariate plots/cell population). (B) Comparable T-cell data via PCA1 vs. PCA2
representation of a 6-dimensional space in six healthy controls (left) as well as in three severe combined immunodeficiency (SCID) patients, diagnosed with Artemis,
PNP and RAG-1 defects, all stained with the RTE/SCID tube under comparable conditions. All three SCID patients show “leakiness” with virtually complete absence
of naïve T-cells (<1 cell/µL blood) and clear “right shift” to mature CM/TM, EM, and TD T-cells in both the CD4 and CD8 lineages.
and phenotypes; and 3. Further sub-classification of PID cases
into distinct diagnostic categories (Figures 2–7).
Stepwise application of the EuroFlow PID tubes according
to the proposed algorithm (Figure 1A) supports the diagnosis
of many PID evaluated so far (n = 233), and provides further
classification of most lymphoid PID cases into distinct diagnostic
categories according to altered flowcytometric immune cell
profiles (Table 5). For example, the PIDOT together with the
IgH-isotype tubes (Figure 8) support the diagnosis of virtually all
IgA- and IgG-subclass deficiencies and CVID patients, including
their detailed characterization (57). Figure 9 shows an example
of combined application of the PIDOT, the Pre-GC tube and
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FIGURE 7 | Application of the T-cell panel tube in healthy controls and PID patients with T-cell defects. Analysis of circulating T-cell subsets (FS/SSloCD3+) identified
within 1 × 106 blood leukocytes using the markers from the T-cell panel tube: naïve (CD45RO− CCR7+ CD27+ CD28+), Central Memory (CM) (CD45RO+ CCR7+
(Continued)
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FIGURE 7 | CD27+ CD28+), Transitional Memory (TM) (CD45RO+ CCR7− CD27+ CD28+/−), Effector Memory (EM) (CD45RO+ CCR7− CD27− CD28+), Terminal
Effector (TE) (CD45RO− CCR7− CD27+ CD28+/−), and Terminally Differentiated (TD) (CD45RO− CCR7− CD27− CD28+/−) CD4+ and CD8+ T-cells. (A) The
identification of biologically relevant subsets of T-cells in six healthy controls using the minimum number of bivariate plots required for a 6 marker-combination (three
bivariate plots/cell population). (B) Comparable data via PCA1 vs. PCA2 representation of a 6-dimensional space in blood of six healthy controls (left) as compared to
blood samples of three severe combined immunodeficiency (SCID) patients, diagnosed with RAG2, PNP, and DOCK8 defects, all stained with the RTE/SICD tube
under comparable conditions. The SCID patients show “leakiness” with absence of naïve T-cells (<1 cell/µL blood) and variable “right shift” to mature CM/TM, EM,
and TD T-cells in the CD4 lineage (all 3 SCID patients) and CD8 lineage (PNP and DOCK8 defects).
TABLE 4 | Composition of the 8-color BM-BCP tube and technical information on reagents.
BV421 BV510 FITC PE PerCPCy5.5 PECy7 APC APCAF750
SCID/RTE panel CD62L CD4 CD45RO CD31 HLA-DR TCRγδ CD3 CD8
T-cell panel CD27 CD4 CD45RO CD197 CD28 TCRγδ CD3 CD8
Marker Fluorochrome Clone Source Catalog number Application in EuroFlow panel µl/test
CD3 APC SK7 BD Biosciences 345767 Orientation, SCID/RTE, T cell subset tubes 2.5
CD4 BV510 OKT4 BioLegend 317443 Orientation, SCID/RTE, T cell subset tubes 1.5
CD8 APCAF750 B9.11 Beckman Coulter A94683 Orientation, SCID/RTE, T cell subset tubes 1.5
CD27 BV421 M-T271 BD Biosciences 562513 Orientation, Pre-GC, Post-GC, T cell subset tubes 1
CD27* BV421 O323 BioLegend 302824 Orientation, Pre-GC, Post-GC, T cell subset tubes 1
CD28 PerCPCy5.5 CD28.2 BioLegend 302921 T-cell subset tube 4
CD31 PE MEM-05 Exbio 1P-273-T100 SCID/RTE tube 5
CD45RO FITC UCHL1 Exbio 1F-498-T100 SCID/RTE, T cell subset tube 10
CD62L BV421 DREG-56 Biolegend 304827 SCID/RTE tube 2
CD197 PE FR 11-11E8 Miltenyi 130-093-621 T cell subset tube 5
HLADR PerCPCy5.5 L243 Biolegend 307629 SCID/RTE tube 1.5
TCRγδ PECy7 11F2 BD Biosciences 649806 Orientation, SCID/RTE, T cell subset tubes 1
*Alternative reagent tested to provide same results.
the T-cell subset tube in a patient with a WASp defect, showing
several aberrancies in T-cell subsets.
More detailed results on the application of the individual
EuroFlow PID tubes and their corresponding reference databases
and age-matched reference values are provided in separate
publications (57, 59) and are implemented in the EuroFlow-
based Infinicyt software, respectively.
DISCUSSION
Diagnosis and classification of rare diseases deserves well-defined
strategies that are efficient and easily accessible, providing a
diagnosis at an early stage, in order to prevent diagnostic delays
with higher chances of irreversible organ damage. In case of PID,
this requires awareness of general practitioners and pediatricians
about the most efficient and cost-effective diagnostic pathways as
proposed by ESID and IUIS (2, 5, 6). These diagnostic pathways
include flowcytometric immunophenotyping at an early stage,
which can guide other diagnostic tests such as functional assays
and genetic studies.
Specialized reference centers are required for full diagnostics
and clinical management of rare diseases such as PID. Broad
and easy access to fast diagnostic screening strategies and linkage
to these highly specialized PID reference centers of excellence
shall reduce morbidity and mortality of PID patients. The
medical indications for testing of PID are well-defined (“the
10 warning signs of PID”) and several consensus reports on
stepwise diagnostic strategies have been proposed (2, 5, 7, 79, 80).
However practical implementation of these consensus proposals
has only partially been achieved. This is mainly due to lack of
standardization in the pre-analytical and analytical laboratory
procedures, particularly in flow cytometry and NGS/WES (9, 10,
43–45). At least in part, this lack of standardization is caused by
the fast technological developments in both fields, which has led
to great variability in technical procedures and assays between
individual laboratories, thereby hampering comparability of
diagnostic results, even among reference PID centers.
The main objectives of the EuroFlow Consortium were
to innovate and standardize the flowcytometric techniques
and strategies, applied in the diagnosis and classification
of PID of the lymphoid system and to generate reliable
and reproducible results across laboratories and countries,
for guiding both functional testing and genetic testing in
flowcytometrically-defined PID subgroups. To achieve these
objectives, the EuroFlow Consortium took advantage of its
concepts, technologies, tools and experience from the field of
leukemia and lymphoma diagnosis, classification andmonitoring
(61–65). Consequently, we sequentially (i) developed 8-color
tubes (and one 12-color BM tube) for efficient diagnostic
testing and classification of PID in multiple multicenter cycles
of design-testing-evaluation-redesign, following strict rules for
selection of optimal combinations of antibody clones and their
fluorochrome conjugates; (ii) validated the approved antibody
tubes in healthy controls and PID patient series (56–59);
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TABLE 5 | Application of EuroFlow PID tubes for the primary immunodeficiency disease categories.
Disease category
(IUIS 2017) (1)
EuroFlow PID tubes
Orientation Pre-GC Post-GC IgH-isotypes SCID/RTE T-cell subset
tube
Frequency correct
diagnosis
Immunodeficiency affecting
cellular and humoral immunity
(n = 36)
Diagnostic screening Exploratory Exploratory Exploratory Clinical
classification
Clinical
classification
100%
5CID with associated or
syndromic features (n = 20)
Diagnostic screening Exploratory Exploratory Exploratory Clinical
classification
Clinical
classification
75%*
Predominantly antibody
deficiencies (n = 150)
Diagnostic screening Clinical
classification
Clinical
classification
Diagnostic screening
and classification
Exploratory Exploratory 100%
Diseases of immune
dysregulation (n = 10)
Diagnostic screening Exploratory Exploratory Exploratory Exploratory Exploratory 90%
Congenital defects of
phagocyte numbers or
functions (n = 10)
Immuno-evaluation Exploratory Exploratory Exploratory Exploratory Exploratory 70%
Defects in intrinsic and innate
immunity (n = 3)
Immuno-evaluation Exploratory Exploratory Exploratory Exploratory Exploratory 67%
Autoinflammatory disorders
(n = 0)
Immuno-evaluation Exploratory Exploratory Exploratory Exploratory Exploratory –
Complement deficiencies
(n = 4)
Immuno-evaluation Exploratory Exploratory Exploratory Exploratory Exploratory 0%
*60% of cases showing normal blood lymphocyte subset counts were DiGeorge Syndrome patients. Diagnostic screening: mandatory for the diagnosis and management of the patient
according to international classifications (1, 2, 5, 40). Clinical classification: required for identification of subgroups of patients with different disease presentation and outcome, including
guiding genetic testing (1, 2, 5, 41, 43). Immuno-evaluation: provides information indicated for treatment decision and patients monitoring (11–13). Exploratory: not required for clinical
management, might provide relevant immune information; CID, Combined Immunodeficiency.
FIGURE 8 | PCA representation of the biologically relevant subsets in a patient diagnosed with IgG2 subclass deficiency with IgA deficiency (40 years). The
distribution of the biologically relevant PB lymphocyte subsets has been represented using multidimensional reference plots. The supervised analysis of the PID
orientation tube using PC1 vs. PC2 reference plots (A) shows that plasmablasts were undetectable in the patient sample after acquiring 1 × 106 cells. Lack of plasma
cells was confirmed in the analysis of the Pre-GC and Post-GC B-cell tubes (B). In addition, three dimensional PCA representation of IgH-isotype subsets in memory
B-cells (C) showed that although the counts of total switched memory B-cells was normal in the previous tubes, the subsets of IgG2+, IgA1+, and IgA2+ were
undetectable with a sensitivity of 10 cells in a mL of peripheral blood (0.01 cells/µL).
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FIGURE 9 | PCA representation of the biologically relevant subsets in a patient diagnosed with a WASp defect (5 years-old). The distribution of the biologically
relevant PB lymphocyte subsets has been represented using multidimensional reference plots. The supervised analysis of the PID orientation tube using PC1 vs. PC2
reference plots (A) shows that low numbers of total and naïve CD8+ T-cells, and unswitched and switched memory B-cells, were detected in the patient sample after
acquiring 1 × 106 cells. Decreased counts of unswitched memory B-cells was confirmed in the analysis of the B-cell tubes (B). In addition, PCA1 vs. PCA2
representation of the T-cell tube (C) confirmed that naïve CD8+ T-cells were decreased.
(iii) constructed reference databases of normal samples and
well-annotated patient samples, which can serve as templates
for prospective data analysis; and (iv) provided the basis for
standardized interpretation of the results obtained in individual
laboratories, which apply the same EuroFlow methods and tools.
As evaluated in more than 240 PID patients, the stepwise
application of the proposed tubes according to the EuroFlow
PID algorithm (Figure 1A) provides efficient and cost-effective
flowcytometric diagnostic screening and classification of virtually
all PID of the lymphoid system, based on fast, sensitive, easy,
and reproducible identification and enumeration of all relevant
subsets (Figure 1). The B-cell tubes have proven to more
accurately dissect the blood memory B-cell and plasmablast
compartments than achieved previously, thereby providing new
possibilities to better diagnose and classify antibody deficiencies,
including IgH-subclass deficiencies and CVID (57). In patients
suspected of SCID (e.g., in the TREC-based NBS programs),
the combined application of the PIDOT and SCID tubes will
be highly informative (14, 75–77). Furthermore, the diagnostic
procedures for secondary immunodeficiencies might profit as
well from the proposed PID tubes and tools (81). Still several
subsets of PID patients might present with no or minimally
altered lymphoid subset numbers, such as in some DiGeorge
patients and part of ALPS, Nijmegen breakage syndrome and
ataxia telangiectasia patients at young age. In such cases
functional and genetic testing are more informative. Finally, in
this study not all types of lymphoid PID could be studied in
large series, implying that more cases of the rare diagnostic PID
categories should be evaluated. This will be a continuous process
to further support the clinical use of the proposed PID tubes; the
EuroFlow Consortiumwill continue to contribute to this process.
Based on our experience in the leukemia and lymphoma
field, we believe that the provided standardized strategies, tools,
and reference databases are cost-effective and can easily be
implemented, not only in specialized PID reference centers, but
in any medical immunology laboratory equipped with an 8-
color flow cytometer in any PID center in the world. However,
it should be noted that standardized flow cytometry, although
critical for PID evaluation, does not replace and has to be coupled
to immunological functional and genetic testing in order to reach
a final diagnosis in most cases.
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